Project cooperation
TIGA is a digital health SME with 18+ years of experience in national-scale health IT. We offer AI/ML analytics, interoperability (FHIR/HIE), and real-world data platforms to support personalised medicine research.(WIDERA option)
- IHI Topic 1: IHI European healthcare incubator network
- Partner offering expertise and is looking for a consortium
- IHI Topic 3: Decode the immuno-science of age-related mediated diseases
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
- HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
- HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
- HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
- HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
- HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
- HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
EU Technology & Funds Manager at TİGA
Ankara, Türkiye